Tarsus Pharmaceuticals (TARS) Current Assets (2019 - 2026)

Tarsus Pharmaceuticals' Current Assets history runs 8 years deep, the most recent figure standing at $537.2 million for Q1 2026.

• In Q1 2026, Current Assets rose 11.74% year-over-year to $537.2 million; the TTM figure through Mar 2026 stood at $537.2 million (up 11.74% YoY), while the FY2025 annual figure was $522.8 million, up 46.56% from the prior year.
• Current Assets for Q1 2026 stood at $537.2 million, up from $522.8 million in the prior quarter.
• The five-year high for Current Assets was $537.2 million in Q1 2026, with the low at $178.8 million in Q1 2022.
• The 5-year median for Current Assets is $340.7 million (2024), against an average of $337.1 million.
• The sharpest annual moves came in 2023 and 2024: Current Assets fell 26.69% in 2023, then surged 97.62% in 2024.
• Tarsus Pharmaceuticals' Current Assets stood at $225.4 million in 2022, then increased by 13.65% to $256.1 million in 2023, then soared by 39.27% to $356.7 million in 2024, then surged by 46.56% to $522.8 million in 2025, then increased by 2.76% to $537.2 million in 2026.
• Business Quant data shows TARS's Current Assets at $537.2 million in Q1 2026, $522.8 million in Q4 2025, and $501.7 million in Q3 2025.